Sanofi-Aventis taking back all Japanese rights to Intal
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis will regain exclusive distribution rights to Intal (sodium cromoglycate) in Japan on 1 January next year following the expiration of an existing contract with Astellas.